Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) EBITDA: 2009-2025

Historic EBITDA for Aytu Biopharma (AYTU) over the last 17 years, with Jun 2025 value amounting to -$7.8 million.

  • Aytu Biopharma's EBITDA fell 61.72% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year decrease of 274.71%. This contributed to the annual value of -$7.8 million for FY2025, which is 259.20% down from last year.
  • Per Aytu Biopharma's latest filing, its EBITDA stood at -$7.8 million for FY2025, which was down 259.20% from -$2.2 million recorded in FY2024.
  • Over the past 5 years, Aytu Biopharma's EBITDA peaked at -$2.2 million during FY2024, and registered a low of -$109.9 million during FY2022.
  • Moreover, its 3-year median value for EBITDA was -$7.8 million (2025), whereas its average is -$9.0 million.
  • As far as peak fluctuations go, Aytu Biopharma's EBITDA surged by 87.23% in 2024, and later slumped by 259.20% in 2025.
  • Aytu Biopharma's EBITDA (Yearly) stood at -$58.9 million in 2021, then crashed by 86.69% to -$109.9 million in 2022, then spiked by 84.47% to -$17.1 million in 2023, then spiked by 87.23% to -$2.2 million in 2024, then tumbled by 259.20% to -$7.8 million in 2025.